Form 4: Voyager Therapeutics Director Steven Hyman Acquires 24,000 Stock Options

Director Steven Hyman acquired 24,000 stock options in Voyager Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing.

Summary

• Steven Hyman, a director of Voyager Therapeutics, Inc., acquired 24,000 stock options on June 5, 2024.
• The options were granted under the company's 2015 Stock Option and Incentive Plan as part of the director compensation policy.
• The exercise price of the stock options is $8.70.
• The options vest upon the earlier of the one-year anniversary of the grant date (June 5, 2024) or the date of the next annual meeting of stockholders, contingent upon continued service as a director.
• The options expire on June 5, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard compensation practice that aligns director interests with shareholders, but doesn't indicate any significant strategic shift or financial impact.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Industry Context

Stock option grants are a common form of compensation for directors of publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary significantly across the biotechnology industry depending on company size, stage of development, and board responsibilities.
• Comparing Voyager Therapeutics' director compensation to companies like Sarepta Therapeutics or BioMarin Pharmaceutical would provide a better understanding of whether the option grant is in line with industry norms.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment as it aligns director interests with those of the shareholders.

Key Dates